Ketoanalogue Supplementation in Chronic Kidney Disease (CKD) Stages 3‑5

Dosing Recommendations

The National Kidney Foundation KDOQI 2020 guideline recommends prescribing 1 ketoanalogue tablet per 5 kg of ideal body weight per day when combined with a very‑low‑protein diet (0.28–0.43 g protein/kg/day) to achieve a total protein intake of 0.55–0.60 g/kg/day; this regimen is supported by Grade 1A evidence for reducing the risk of end‑stage kidney disease (ESKD) or death【1】【2】【3】【4】【5】.
A 1‑tablet‑per‑10‑kg regimen lacks any published clinical trial data or guideline endorsement, providing insufficient essential amino‑acid supplementation to meet the total protein target and potentially compromising nutritional status【5】.

CKD stage 3‑5 (eGFR < 60 mL/min/1.73 m²) patients not on dialysis are the target population for ketoanalogue supplementation【1】【2】【3】【4】【5】.
Candidates must be metabolically stable (no acute or critical illness) and have adequate baseline nutritional status (stable weight, acceptable serum albumin)【1】【2】【3】【4】【5】.
Non‑diabetic patients receive the strongest recommendation for this regimen; diabetic patients may be managed with a slightly higher protein intake (0.6–0.8 g/kg/day) without ketoanalogues【1】【2】【3】【4】【5】.

Ongoing supervision by a registered dietitian nutritionist and the treating physician is mandatory to ensure safety and adherence【1】【2】【3】【4】【5】.
Clinical monitoring every 3 months should include eGFR, serum urea, creatinine, albumin, bicarbonate, calcium, and phosphorus, together with assessments of body weight, BMI, and lean body mass (though specific frequency citations are “ignore ref,” the requirement for regular monitoring is endorsed by the guideline)【1】【2】【3】【4】【5】.
Dietary compliance should be evaluated using 3‑day food records to verify protein and energy intake targets【1】【2】【3】.

Hospitalized patients with acute illness should not follow protein restriction; they require 1.0–1.2 g/kg protein to meet catabolic demands【6】.
Critically ill patients with acute kidney injury (AKI) should also avoid protein reduction aimed at delaying dialysis【6】.
Patients on chronic dialysis (CKD 5D) need higher protein intake (1.0–1.2 g/kg/day) and ketoanalogue supplementation is not indicated【1】【2】【3】【4】【5】.

The KDOQI 2020 guideline (Kidney Disease Outcomes Quality Initiative) explicitly recommends ketoanalogue supplementation with very‑low‑protein diets to meet total protein requirements, assigning Grade 1A evidence for the reduction of ESKD/death risk【1】【2】【3】【4】【5】.
Multiple randomized controlled trials (2023, 2018, 2016, 2007, 1987) have consistently employed the 1‑tablet‑per‑5‑kg dosing strategy and demonstrated benefits such as delayed eGFR decline, improved cardiovascular parameters, deferred dialysis initiation (NNT ≈ 4), and reduced need for renal replacement therapy (4 % vs 27 %)—all supporting the guideline recommendation (these trial citations are marked “ignore ref” and therefore not listed individually).

All patient‑specific data have been generalized to protect privacy.

Patients on a very‑low‑protein diet combined with ketoanalogue tablets should consume more than 30 kcal per kilogram of body weight per day to prevent malnutrition and ensure the metabolic benefits of the regimen 7, 8.

In CKD stage 3 patients, a meta‑analysis showed that a standard low‑protein diet (≈0.6 g/kg/day) without ketoanalogues results in little or no difference in the rate of progression to kidney replacement therapy compared with a normal protein intake. 9, 10
Providing protein intake below 0.5 g/kg/day together with ketoanalogue supplementation produces a significant reduction in mortality and the need to start dialysis in CKD patients. 9, 10

In patients older than 65 years with eGFR < 20 mL/min/1.73 m², specialist‑directed ketoanalogue supplementation was demonstrated to be safe, with no significant changes in nutritional status or mortality risk. 10